Marinus Pharmaceuticals, Inc. - Common Stock (NQ:MRNS)

0.5500 UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 10, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Marinus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Marinus Pharma: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

May 11, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

May 09, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

May 03, 2023

From Marinus Pharmaceuticals

Via Business Wire

Where Marinus Pharma Stands With Analysts ↗

April 25, 2023

Via Benzinga

RBC Capital Maintains Outperform Rating for Marinus Pharma: Here's What You Need To Know ↗

March 08, 2023

Via Benzinga

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 11, 2023

April 27, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors

April 18, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 06, 2023

From Marinus Pharmaceuticals

Via Business Wire

6 Analysts Have This to Say About Marinus Pharma ↗

March 08, 2023

Via Benzinga

Earnings Outlook For Marinus Pharmaceuticals ↗

March 06, 2023

Via Benzinga

Noting Strong Progress On Marinus Pharma's Lead Drug Ganaxolone, Analyst Initiates With 300% Upside ↗

January 20, 2023

Via Benzinga

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

March 22, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 07, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 06, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharma, Tenacia Biotech Ink Ganaxolone Agreement In China ↗

November 17, 2022

Via Benzinga

Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023

February 13, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

February 07, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors

January 30, 2023

From Marinus Pharmaceuticals

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023 ↗

January 20, 2023

Via Benzinga

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update

January 05, 2023

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

December 09, 2022

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting

November 30, 2022

From Marinus Pharmaceuticals

Via Business Wire

Week In Review: Fosun Signs $840 Million Deal For US Rights To Henlius' PD-1 ↗

November 19, 2022

Fosun Pharma announced it has licensed US rights to a PD-1 candidate from Henlius Biotech in an $840 million agreement. Meanwhile, Tenacia Biotechnology in-licensed greater China rights to a seizure...

Via Talk Markets

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

November 18, 2022

From Marinus Pharmaceuticals

Via Business Wire

Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board

November 17, 2022

From Marinus Pharmaceuticals, Inc.

Via Business Wire

Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China

November 17, 2022

From Marinus Pharmaceuticals

Via Business Wire

Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday ↗

November 09, 2022

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.